Lung Cancer Drug Intervention Study
(Redirected from Lung Cancer Clinical Trial)
Jump to navigation
Jump to search
A Lung Cancer Drug Intervention Study is a cancer drug intervention study for a lung cancer drug (for lung cancer).
- Context:
- It can range from being a Small-Scale Lung Cancer Drug Clinical Research Intervention Study to being a Large-Scale Lung Cancer Drug Clinical Research Intervention Study.
- It can range from being a Regional Lung Cancer Drug Clinical Intervention Study (such as an India Lung Cancer Drug Clinical Trial) to being a Global Lung Cancer Drug Clinical Intervention Study.
- It can range from being a Government-lead Lung Cancer Drug Clinical Trial to being an Organizational-led Lung Cancer Drug Clinical Trial, such as a Merck-led lung cancer drug clinical trial.
- It can range from being a Centralized Lung Cancer Drug Clinical Trial (with clinical research intervention site) to being a Decentralized Lung Cancer Drug Clinical Trial (with direct to patient assessments).
- It can range from being a Phase 1 Lung Cancer Drug Clinical Study, to being a Phase 2 Lung Cancer Drug Clinical Study to being a Phase 3 Lung Cancer Drug Clinical Study to being a Phase 4 Lung Cancer Drug Clinical Study.
- It can be associated with a Lung Cancer Clinical Outcome Assessment (COA).
- …
- Example(s):
- See: Overall Survival (OS), Lung Cancer Biomarker.
References
2021
- https://www.frontiersin.org/articles/10.3389/fonc.2021.672916/full
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...
... Furthermore, high-quality real-world evidence (RWE) could be leveraged to enable drug approvals in oncology, linking it to the value proposition of drugs. Regulatory bodies, such as the US Food and Drug Administration, have recently shown a willingness to expedite access to new cancer medicines by using RWE ...
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...
2006
- (Du et al., 2006) ⇒ Wei Du, Shirish M. Gadgeel, and Michael S. Simon. (2006). “Predictors of Enrollment in Lung Cancer Clinical Trials.” Cancer: Interdisciplinary International Journal of the American Cancer Society 106, no. 2
- QUOTE: ... To assess enrollment rates and factors that are predictive of enrollment onto lung cancer clinical trials, we evaluated the clinical trials enrollment experience at a large academic medical center in Metropolitan Detroit. ...
1994
- (Bergman et al., 1994) ⇒ B. Bergman, N. K . Aaronson, S. Ahmedzai, S. Kaasa, and M. Sullivan. (1994). “The EORTC QLQ-LC13: A Modular Supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for Use in Lung Cancer Clinical Trials.” European Journal of Cancer 30, no. 5
1972
- (Bergsagel et al., 1972) ⇒ D. E . Bergsagel, R. D. T. Jenkin, J. F . Pringle, D. M . White, J. C. M . Fetterly, D. J . Klaassen, and R. S. R. McDermot. (1972). “Lung Cancer: Clinical Trial of Radiotherapy Alone Vs. Radiotherapy Plus Cyclophosphamide.” Cancer, 30(3).